Medtronic Announces Three Major Executive Appointments in May 2026

　　【Pharmaceutical Network Corporate News】In May 2026, Medtronic successively announced a series of major executive appointments, indicating that the company has implemented a new management structure across its supply chain, neuroscience, and cardiovascular surgery divisions.
 

Recent reports indicate that Brett Wall, Executive Vice President and President of Medtronic’s Neuroscience portfolio, will step down, with the appointment of his successor taking effect on June 1. It is understood that prior to joining Medtronic, Brett Wall held positions at ev3, Micro Therapeutics, and Boston Scientific, among others. The incoming successor is Dr. Kweli Thompson, who currently serves as Senior Vice President and President of Medtronic’s Cardiac Rhythm Management business.
 

On May 13, Medtronic announced the appointment of Rogerio Branco as Senior Vice President and Chief Operating & Supply Chain Officer, effective immediately. Public records indicate that Branco previously served as Executive Vice President and Chief Operating & Supply Chain Officer at Eaton, a power management company headquartered in Dublin, Ireland, where he oversaw integrated materials management and inventory, procurement, logistics, supplier development, and quality. Upon joining Medtronic, he will lead the strategy and execution of the company’s end-to-end operations and supply chain to drive reliability, efficiency, and growth while serving patients and customers worldwide.
 

On May 6, Medtronic completed a major business restructuring, merging its Cardiac Surgery and Aortic divisions into Cardiovascular Surgery. Following the merger, the newly established business will be led by Karim Bandali. It is reported that Simona Zannetti, former head of the Aortic business, departed in early 2026.
 

In addition to frequent personnel adjustments, Medtronic has also executed multiple acquisitions and divestitures in its business operations this year. On May 20, Medtronic announced that it has agreed to acquire all issued and outstanding shares of chronic pain management company SPR Therapeutics in cash for approximately $650 million (about RMB 4.4 billion). SPR Therapeutics’ core product is the Sprint Peripheral Nerve Stimulation (PNS) System, which received FDA approval for commercialization in 2018. As of the end of 2025, cumulative implants of this device have surpassed 50,000 cases.
 

On April 20, Medtronic announced the completion of its acquisition of CathWorks, an artificial intelligence cardiac technology developer, for a total transaction value of up to $585 million. It is reported that CathWorks specializes in revolutionizing the diagnostic and therapeutic paradigms for coronary artery disease (CAD). Medtronic had already acquired a minority stake in the company as early as 2018.
 

On March 10, Medtronic announced the acquisition of neurovascular device company Scientia Vascular for $550 million (approximately RMB 3.9 billion). The transaction is expected to close in the first half of fiscal year 2027. Scientia has been deeply engaged in the neurointerventional sector for years, with its core products comprising precision consumables essential for stroke procedures, such as microguidewires and microcatheters.
 

In the same month, Medtronic's diabetes business was officially spun off into an independent company, MiniMed, and listed on Nasdaq. The company issued 28 million shares at an offering price of $20 per share, raising approximately $560 million in total.
 

In summary, in 2026, Medtronic is pursuing a three-pronged strategy of organizational streamlining, targeted M&A, and senior leadership reshuffling, aiming to build new competitive advantages in high-growth sectors such as cardiovascular and neuroscience. Whether it can deliver the accelerated growth anticipated by the market will likely depend primarily on the integration effectiveness of its neurovascular portfolio and the capital allocation efficiency following the divestiture of its diabetes business.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed herein constitute investment advice to any person.